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Abstract
Von Willebrand Disease (vWD) is the
most common inherited bleeding
diathesis worldwide and results in
defects in von Willebrand Factor
(vWF), inducing a hypocoagulable
state. Polycystic Ovary Syndrome
(PCOS) is characterized by chronic
inflammation and hyperestrogenism,
both of which induce acute phase
reactions and increase serum levels
of vWF and Factor VIII, yielding a
prothrombotic state. These laboratory
elevations may obscure the diagnosis
of underlying vWD in patients with
both conditions.
We report a case of a 23 year-old
female with PCOS and menorrhagia
who presented prior to a surgical
procedure for evaluation of bleeding
risk. Evaluation for vWD was within
normal limits. However, Factor IX
assay was significantly elevated at
218% (60-150%), and
thromboelastography (TEG) showed
elevated MA and G, consistent with
platelet hypercoagulability and
increased clot strength. Subsequent
review of remote external records
determined that the patient had a
previous evaluation for a bleeding
disorder at age three and was
diagnosed with type I vWD at that
time. To the best of our knowledge,
this is the first reported case of
coexisting PCOS and vWD resulting in
a false negative workup for underlying
vWD. Management of such patients
with superimposed hypercoagulable
and hypocoagulable states,
particularly perioperatively, may be
complex.
DISCUSSION
CONCLUSIONS
In this case report, a patient with PCOS
and a remote diagnosis of type I vWD had
elevation of vWF levels into the normal
range, and current laboratory workup did
not reflect the underlying bleeding
diathesis but rather was consistent with a
hypercoagulable state.
Despite the high prevalence of vWD and
the characteristic clinical picture,
laboratory confirmation of vWD can be
challenging, as both vWF and Factor VIII
are elevated by inflammatory acute-phase
reactions and hyperestrogenism.
PCOS induces a hypercoagulable state
associated with hyperestrogenism and
elevated vWF levels, which can result in a
false negative workup for underlying vWD.
We have proposed a model for PCOS-
induced hypercoagulability, as follows:
Pathogenesis of vWD and PCOS
Clinical History Laboratory Values Thromboelastography
A 23 year-old female with a BMI of 41
presented with a chief complaint of
menorrhagia. She has 1-2 menstrual
cycles per year, lasting 30-90 days
each, during which she experiences
heavy bleeding. Her medical history is
significant for easy bruising,
prolonged bleeding after surgical
procedures, and PCOS. Her family
history is significant for an unknown
bleeding diathesis in her maternal
grandmother. The patient was
diagnosed with type I vWD at age
three, following prolonged bleeding
after tonsillectomy. However, multiple
subsequent laboratory evaluations for
vWD performed by different clinicians
were within normal limits (WNL).
Elevated MA indicates platelet hypercoagulability.
Elevated G indicates increased clot strength.
38.8% inhibition with ADP (normal <20%).
vWF normally serves to facilitate coagulation and to protect Factor VIII from peripheral degradation. vWD decreases vWF levels,
causing a hypocoagulable state. However, levels of vWF and Factor VIII are susceptible to fluctuations. vWF and Factor VIII are
acute phase reactants, and even mild stimulation of the acute-phase response can yield a falsely normal vWD workup.1 Estrogen
also increases levels of vWF, Factor VIII, and Factor IX. In PCOS, vWF and Factor VIII levels are increased due to inflammation
and hyperestrogenism. PCOS also increases circulating levels of fibrinogen and PAI-1, yielding a prothrombotic state.
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Age 3
Prolonged bleeding after 
tonsillectomy
Age 23
Self-referred to UMH 
• PTT 36.1 (21.0-31.0)
• Repeat PTT 35.2, corrected after 
mixing study (29.9)
• Factor VIII, IX, XI, and XII WNL
• Diagnosed with type I vWD 
• PT, PTT, vWF multimers WNL
• Factor IX 218% (60-150)
• vWF antigen 84% (55-200)
• vWF activity 68% (55-200)
• Factor VIII 75% (55-200)
• Blood type A Positive
Adapted from Manners-Holm2 and Koiou3.
Normal TEG:
Patient’s TEG:
Figure 1. Normal physiology of primary hemostasis. Figure 2. Schematic of patient’s coagulation state.
